RTT

Positive data from Sanifit’s Phase 2b CaLIPSO trial of SNF472 published in Circulation

Tuesday, November 12, 2019 - 7:00am

The trial met its primary endpoint, demonstrating significantly reduced progression of coronary artery calcium (CAC) volume in patients treated with SNF472 compared to placebo.

Key Points: 
  • The trial met its primary endpoint, demonstrating significantly reduced progression of coronary artery calcium (CAC) volume in patients treated with SNF472 compared to placebo.
  • The CaLIPSO trial was a 52-week, double-blind, randomized, placebo-controlled trial assessing SNF472, a selective inhibitor of the formation and growth of hydroxyapatite crystals, in patients with ESKD on hemodialysis.
  • Patients were randomized 1:1:1 to SNF472 300 mg (n=92), SNF472 600 mg (n=91), or placebo (n=91) thrice weekly during hemodialysis sessions.
  • We look forward to reviewing the data further as we continue clinical development of SNF472.

Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019

Tuesday, November 12, 2019 - 7:00am

POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting 2019 hosted by the American Association for the Study of Liver Diseases (AASLD).
  • In the poster presentation, PXL065 was observed to have a favorable safety, tolerability and PK profile in the Phase 1a trial.
  • Based on preclinical and clinical results, I am excited about the potential for an improved therapeutic profile for PXL065 compared to pioglitazone.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.

Barts Cancer Institute and HistoGeneX Published Novel Research in Nature Medicine

Tuesday, November 12, 2019 - 7:10am

ANTWERP, Belgium, Nov. 12, 2019 /CNW Telbec/ -Today in Nature Medicine , researchers from Barts Cancer Institute (London), Queen Mary University of London together with pathologists from HistoGeneX (Belgium), a laboratory focused ontissue pathology and genomics, published findings that may significantly alter the treatment of bladder cancer.

Key Points: 
  • ANTWERP, Belgium, Nov. 12, 2019 /CNW Telbec/ -Today in Nature Medicine , researchers from Barts Cancer Institute (London), Queen Mary University of London together with pathologists from HistoGeneX (Belgium), a laboratory focused ontissue pathology and genomics, published findings that may significantly alter the treatment of bladder cancer.
  • In the study, 95 patients with invasive bladder cancer received two cycles of anti-PDL1 before their cystectomy was performed.
  • The initial bladder biopsies collected for diagnosis were compared with the bladder resections to investigate the nature of the responses.
  • The Barts Cancer Institute (BCI) was created in 2003, and brought together some of the most eminent cancer research teams in London.

Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by Route of Administration, by End User, by Geography Global Market Size, Share, Development, Growth, and Demand Forecast, 2014-2024

Monday, November 11, 2019 - 10:20pm

Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD.

Key Points: 
  • Eylea, Lucentis, and Avastin are the drugs available worldwide for the treatment of wet AMD.
  • The major factors escalating the demand for this drug in the global wet age-related macular degeneration market are the rising prevalence of AMD.
  • In 2018, North America held the largest revenue share, amounting to nearly $3.0 billion, in the global wet age-related macular degeneration market.
  • Thus, the increasing government initiatives are boosting the wet age-related macular degeneration market growth in the APAC region.

IBM, American Cancer Society, National Comprehensive Cancer Network, Clinton Health Access Initiative, and African Cancer Coalition Establish New Alliance to Help Fight Cancer in Sub-Saharan Africa

Monday, November 11, 2019 - 10:00pm

The Alliance will support a network of African oncology experts and technical assistance partners to help improve the quality of cancer care, including collaborating closely with the African Cancer Coalition to establish priorities and execute these initiatives locally.

Key Points: 
  • The Alliance will support a network of African oncology experts and technical assistance partners to help improve the quality of cancer care, including collaborating closely with the African Cancer Coalition to establish priorities and execute these initiatives locally.
  • There are more than 800,000 new cancer cases each year in Sub-Saharan Africa and incidence is projected to double by 2040.
  • And as these countries address the growing cancer epidemic, data and emerging technologies can play a significant role in cancer treatment control and care.
  • The need for more affordable cancer treatment and strong systems for their delivery are crucial to help improve patients' survival.

Endologix, Inc. to Present at the Stifel Healthcare Conference

Monday, November 11, 2019 - 9:01pm

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m.

Key Points: 
  • Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m.
  • A live webcast of the presentation will be accessible through the Investors section of the Companys website at www.endologix.com and will be available for replay following the event.
  • AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.
  • The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States.

Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

Monday, November 11, 2019 - 4:00pm

The trial achieved its primary efficacy endpoint by demonstrating a statistically significant reduction in HbA1c levels over placebo during the first 24 weeks of the trial.

Key Points: 
  • The trial achieved its primary efficacy endpoint by demonstrating a statistically significant reduction in HbA1c levels over placebo during the first 24 weeks of the trial.
  • Our Phase III trial HMM302 [NCT03141073] targets patients who have failed metformin treatment and has recently completed enrollment.
  • HMM0301 [NCT03173391] is a randomized, double-blind, placebo-controlled Phase III study in 463 drug nave type 2 diabetes patients.
  • 1 Defined as less than 3.0 mmol/liter per the American Diabetes Association Standards of Medical Care in Diabetes 2019.

Epzicom - Drug Insight Report, 2019-2021 - ResearchAndMarkets.com

Monday, November 11, 2019 - 7:14pm

The "Epzicom - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Epzicom - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Epzicom - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of the Epzicom covering the historical global sales and also provides the Epzicom sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Epzicom and emerging therapies in this space.

United States Automated Insulin Delivery System Market Report 2019 - Prospects, Trends Analysis, Market Size and Forecasts up to 2025 - ResearchAndMarkets.com

Monday, November 11, 2019 - 5:45pm

The "United States Automated Insulin Delivery System Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Automated Insulin Delivery System Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the United States automated insulin delivery system market provides a detailed analysis of segments in the market based on disease type, and end user.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of automated insulin delivery system market in the United States.
  • 5) What are the modes of entering the United States automated insulin delivery system market?

The exosomes market is expected to register a CAGR of nearly 18.0% during the forecast period, 2019

Monday, November 11, 2019 - 7:20pm

The exosomes market is expected to register a CAGR of nearly 18.0% during the forecast period, 2019-2024.

Key Points: 
  • The exosomes market is expected to register a CAGR of nearly 18.0% during the forecast period, 2019-2024.
  • - The growing prevalence of cancer patients has a direct impact on the increased demand for the exosomes market.
  • - Exosomes extracted from cow milk is being used for the delivery of therapeutic molecules against lung and breast cancers.
  • This is one of the primary hindrances for the growth of the exosomes market.